Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by longondmxon Dec 29, 2009 9:27am
484 Views
Post# 16622267

Market value vs Real value example

Market value vs Real value exampleThe big difference between market value vs actual value can clearly be seen with the following stock:

Bancorp (BKP - Toronto)

Trading around
.80 in November and now is at $1.39 and very likely to be much higher soon.

Bancorp's price increased to something much closer to its actual value of $2.50 because an investment firm is trying an unsolicited takeover of the company at only $1.22 per share.

Bancorp's response to the offer:

The C.A. Bancorp Board believes that Maxam’s $1.22 per share fails to provide full value for C.A. Bancorp’s assets and shares and is an attempt by Maxam to acquire C.A. Bancorp without offering adequate consideration to C.A. Bancorp shareholders. The Board cited a number of reasons for its recommendation, including that:
• Maxam’s offer is inadequate, as it significantly undervalues C.A. Bancorp’s assets and business. Maxam’s offer price represents a 49.9% discount to net asset as of September 30, 2009. The offer does not reflect the value of C.A. Bancorp’s assets, including its core private entity investment which has achieved an implied IRR of approximately 20% from inception to September 30, 2009.
• C.A. Bancorp’s cash, public investments (including Charter REIT and C.A. Bancorp Canadian Realty Finance ) and marketable securities alone have an aggregate value of $1.03 per share. Maxam’s offer is an attempt to use C.A. Bancorp’s own assets to acquire the Company and to thereby appropriate the excess value of the Company for itself.
• The timing of Maxam’s offer is opportunistic and is prejudicial to C.A. Bancorp and its shareholders.
• The Board has initiated a process under which superior proposals, delivering greater value for shareholder, may emerge.
• Maxam’s offer is extremely conditional, to the point where it is not a firm offer.
• Maxam’s offer is at a discount to recent trading prices. In fact, subsequent to its offer, Maxam itself has purchased Company shares at a premium to its offer price.



Not trying to pump this stock (although there are many reasons why the share price should go much higher), just trying to respond to someone's post about NRI's share price and what it should be.
Bullboard Posts